A key gene that helps to explain an underlying cause of incurable bowel disorders such as Crohn’s disease has been identified by scientists at the Universities of Edinburgh and Bristol.
It may not be immediately apparent what volcanoes, artificial intelligence and the Arctic all have in common. Yet they are all subjects of ground-breaking University of Bristol research which was celebrated this week at an event to commemorate 10 years of the European Research Council.
A new study is the first to explore the effect of misinformation on Twitter about e-cigarette harms.
Are there better ways to diagnose animals in need of antibiotics on livestock farms? How will farmers and veterinarians use novel diagnostics in the fight against animal disease? These are some questions a consortium of seven academics – including two veterinarians from the University of Bristol's School of Veterinary Sciences - will address thanks to a £1.75 million grant to understand how better diagnostics can encourage responsible antibiotic use in animals.
The University of Bristol is ninth in the UK and one of 12 UK institutions in the top 100 universities worldwide, according to the latest Times Higher Education (THE) World University Rankings.
An estimated one in five pregnant women around the world carry Group B Streptococcus (GBS) bacteria which is a major, yet preventable, cause of maternal and infant ill health globally.
Estimates suggest that 40 per cent of eczema flares are treated with topical antibiotics, but findings from a study involving academics from the University of Bristol’s Centre for Academic Primary Care, suggest there is no meaningful benefit from the use of either oral or topical antibiotics for milder clinically infected eczema in children.
Four University of Bristol academics have achieved the rare distinction of being elected Fellows of the world’s most eminent and oldest scientific academy in continuous existence, the Royal Society.
A new consortium to accelerate the discovery of novel drugs to treat kidney diseases is announced today [Monday 6 November]. The NEPLEX (nephron on a chip with cellular and extracellular matrix complexity) consortium, comprising leading academic institutions including the Universities of Bristol and Cambridge, and Evotec AG, will combine key technologies to develop and build a novel drug discovery device ("Nephron-on-a-Chip").
The University of Bristol has been ranked 19th in the Times and Sunday Times Good University Guide 2017 - a rise of one place on last year.
